OLF1R Olaines Kimiski - Farmaceitiska Rupnica

Olainfarm Starts the Year With 40% Sales Increase

Olainfarm Starts the Year With 40% Sales Increase

Consolidated sales – January

Preliminary consolidated results of AS Olainfarm for January 2019 show that sales of the Group have reached 12.4 million euros, which represents an increase by 35% compared to sales made in January 2018.

According to consolidated sales figures of January three major sales markets of the Group were Latvia, where sales grew by 16%, Russia, where during the same period sales have grown by 78% and Belarus with 32% sales increase.  From 10 biggest sales markets the sales have shrunk only in Uzbekistan (by 8%). All other of top 10 markets have demonstrated sales increases, the biggest ones coming from Turkmenistan (437%), Moldova (308%) and The Netherlands (246%).

 January 2019, consolidated sales Sales, Thsnd. EURShare in total sales Changes to January 2018
Latvia3 39727%16%
Russia3 05525%78%
Belarus2 23618%32%
Ukraine1 50812%36%
The Netherlands3363%246%
Turkmenistan2512%437%
Germany2442%17%
Poland2192%27%
Uzbekistan1571%-8%
Moldova1271%308%
Other8897%-13%
Total12 419100%35%

Unconsolidated sales – January

According to preliminary unconsolidated sales figures of AS Olainfarm for January, the company made sales worth 9.9 million euros, which represents an increase by 40% compared to the same period of 2018. The main growth drivers were sales increases in Turkmenistan (by 437%), The Netherlands (by 246%) and Russia (by 91%).  The only country with some sales reduction was Uzbekistan (-8%)

January 2019, unconsolidated salesSales, Thsnd. EURShare in total salesChanges to January 2018
Russia2 83329%91%
Belarus1 92919%29%
Latvia1 64717%10%
Ukraine1 50815%36%
The Netherlands3363%246%
Turkmenistan2513%437%
Germany2442%18%
Poland2192%65%
Uzbekistan1572%-8%
Spain1141%NA
Other6957%-18% 
Total9 934100%40%

Performance of Daughter Companies in January

Sales of SIA Latvijas Aptieka in January 2019 reached 2.3 million euros, which represents an increase by 16% compared to January of 2018.  Seventy pharmacies were operating during this period.  Sales of SIA Silvanols during January reached 0.48 million, which also represents 16% increase compared to January 2018.  Sales of elastic medical companies Tonus Elast and Elast Medical reached 0.53 million euros, sales of health care providers Olainmed and Diamed reached 0.23 million euros, but sales of Belarus based NPK Biotest were as high as 0.27 million euros.

 January 2019
Sales markets of Olainfarm 28
Sales markets of the Group32
Number of Latvijas Aptieka pharmacies70
Sales of Latvijas Aptieka thsnd.  2 345
Sales of Olainmed and Diamed thsnd.    232
Sales of NPK Biotest thsnd.  265
Sales of Tonus Elast and Elast Medical, thsnd.   529
Sales of Silvanols, thsnd. 485







 JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top -quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Information prepared by:

        

Inga Krūkle

Member of the Board JSC Olainfarm

Ph.:

EN
15/02/2019

Underlying

Reports on Olaines Kimiski - Farmaceitiska Rupnica

 PRESS RELEASE

Delisting of AS "Olainfarm” shares from the Baltic Main list

Delisting of AS "Olainfarm” shares from the Baltic Main list Delisting of AS "Olainfarm” shares from the Baltic Main list With this AS "Olainfarm” informs, that Nasdaq Riga decided on January 7, 2022 to approve the application of AS "Olainfarm” and to delist its shares (ISIN LV0000100501, Ticker OLF1R) from the Baltic Main List. The last listing day of AS "Olainfarm” is set to January 10, 2022. Additional information:  Jānis LeimanisJSC Olainfarm Member of the Management BoardTel. E-pasts:

 PRESS RELEASE

AS "Olainfarm” akcijas izslēdz no Baltijas Oficiālā saraksta

AS "Olainfarm” akcijas izslēdz no Baltijas Oficiālā saraksta AS "Olainfarm” akcijas izslēdz no Baltijas Oficiālā saraksta Ar šo AS "Olainfarm” informē, ka Nasdaq Riga š.g. 7. janvārī pieņēma lēmumu apstiprināt AS "Olainfarm” akciju (ISIN LV0000100501, Biržas kods OLF1R) izslēgšanu no Baltijas Oficiālā saraksta, par pēdējo akciju kotācijas dienu nosakot 2022. gada 10. janvāri. Papildu informācija:Jānis LeimanisAS “Olainfarm” valdes loceklisTel. E-pasts:

 PRESS RELEASE

Notification about results of final buy-back of shares

Notification about results of final buy-back of shares Notification about results of final buy-back of shares Target company Joint Stock Company " Olainfarm ", registration number  40003007246, legal address: Rupnicu str. 5, Olaine, LV-2114, Latvia, phone: (+371) 67013705, e-mail:  , website: , hereinafter - Target Company.  Offeror AS “AB CITY”, registration number 40203174414, date and place of registration 11.10.2018., Rīga, legal address: Ganību dambis 24D, Riga, LV-1005, e-mail:  , website: , hereinafter - Offeror. Number of shares offered for sale A total of 549 8...

 PRESS RELEASE

Paziņojums par galīgās akciju atpirkšanas rezultātiem

Paziņojums par galīgās akciju atpirkšanas rezultātiem Paziņojums par galīgās akciju atpirkšanas rezultātiem Mērķa sabiedrība Akciju sabiedrība „Olainfarm”, reģistrācijas numurs 40003007246, juridiskā adrese: Rūpnīcu iela 5, Olaine, Olaines novads, LV-2114, tālr. (+371) 67013705; e-pasts: , mājaslapas adrese: , turpmāk – Mērķa sabiedrība. Piedāvātājs AS “AB CITY”, reģistrācijas numurs 40203174414, reģistrācijas datums un vieta 11.10.2018., Rīga, juridiskā adrese: Ganību dambis 24D, Rīga, LV-1005, e-pasts: , mājaslapas adrese: , turpmāk - Piedāvātājs. Pārdošanai p...

 PRESS RELEASE

Notification about final share buy-back

Notification about final share buy-back Joint stock company “Olainfarm”, hereinafter referred to as - “the Company”, hereby informs that by decision No. 185 of 28th December 2021, the Financial and Capital Market Commission allowed AS “AB CITY”, registration number 40203174414, to carry out the Company’s  final share buy-back. Final buy-back price is 9,26 EUR per share. The value of one share has been calculated in accordance with Section 74, Paragraphs one, Clause 3 of the Financial Instruments Market Law. The entry date is the next working day after the date of publishing the informati...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch